Cargando…
Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis
BACKGROUND: Biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs are used in patients with psoriatic arthritis (PsA), but few studies directly compare their clinical efficacy. In such situations, network meta-analysis (NMA) can inform evidence-based decision-making....
Autores principales: | Ruyssen-Witrand, Adeline, Perry, Richard, Watkins, Clare, Braileanu, George, Kumar, Gayathri, Kiri, Sandeep, Nott, Debby, Liu-Leage, Soyi, Hartz, Susanne, Sapin, Christophe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046955/ https://www.ncbi.nlm.nih.gov/pubmed/32094304 http://dx.doi.org/10.1136/rmdopen-2019-001117 |
Ejemplares similares
-
Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta–analysis of randomised controlled trials
por: Champs, Bénédicte, et al.
Publicado: (2019) -
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52
por: Smolen, Josef S, et al.
Publicado: (2020) -
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
por: Mease, Philip J, et al.
Publicado: (2020) -
Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries
por: Lucasson, Florian, et al.
Publicado: (2022) -
Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis
por: Zhang, Hanzhe, et al.
Publicado: (2021)